Ultragenyx Pharmaceutical Inc
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease. The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
Did you know?
Capital expenditures decreased by 14% from FY24 to FY25.
Current Price
$24.77
+0.32%GoodMoat Value
$28.14
13.6% undervaluedProfile
Valuation (TTM)
Market Cap$2.39B
P/E-4.16
EV—
P/B—
Shares Out96.48M
P/Sales3.55
Revenue$673.00M
EV/EBITDA—
Ultragenyx Pharmaceutical Inc (RARE) Stock News
RARE Stock News & Headlines
Latest stock news and headlines for Ultragenyx Pharmaceutical Inc (RARE). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $24.77. Market cap: $2.39B. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to RARE from financial news sources, helping investors stay current on events that may impact Ultragenyx Pharmaceutical Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Ultragenyx Pharmaceutical Inc (RARE).